| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 100mg |
|
||
| 500mg |
| Targets |
Lobenzarit sodium exerts its immunomodulatory effects through actions on T cells, particularly influencing regulatory and helper T lymphocyte subsets. It has been shown to inhibit polyclonal B-cell activation, which may help prevent autoimmune diseases. Its mechanism likely involves modulation of immune responses and cytokine production central to rheumatoid arthritis pathogenesis. The compound also interacts with various enzymes and biomolecules, inhibiting guanosine 3' production.
|
|---|---|
| ln Vitro |
Lobenzarit disodium (CCA) has an IC50 of 1.6 μM and inhibits chemiluminescence generated by reactive oxygen species[1]. The inhibition of peroxide-induced chemiluminescence by Lobenzarit disodium (0.3-300 μM) has an IC50 of 1.6 μM[1].
Lobenzarit sodium inhibits chemiluminescence generated by reactive oxygen species with an IC50 of 1.6 μM. It inhibits peroxide-induced chemiluminescence in a concentration-dependent manner (0.3-300 μM). This antioxidant activity contributes to its anti-inflammatory effects observed in vitro. The compound demonstrates antioxidant properties that may underlie its therapeutic potential in inflammatory conditions. |
| ln Vivo |
In Sprague-Dawley rats, Lobenzarit sodium administered via intraperitoneal injection at doses of 10 and 50 mg/kg once daily for 7 days demonstrated anti-arthritic effects. Importantly, no therapeutic effect was observed in T lymphocyte-depleted arthritic rats, confirming that its immunomodulatory activity depends on functional T cells. This finding validates the compound's mechanism of action through immune system modulation rather than direct anti-inflammatory activity.
|
| Enzyme Assay |
Non-cell-based binding assays for Lobenzarit sodium involve radioligand displacement studies using membrane preparations from cells expressing relevant receptors. Test compounds are incubated with receptor-containing membranes and a radiolabeled ligand; binding affinity is determined by measuring IC50 values. Assays are performed in buffered solutions at physiological pH with appropriate incubation times. Separation of bound and free ligand is achieved through filtration or centrifugation, followed by scintillation counting to quantify bound radioactivity.
|
| Cell Assay |
In vitro cellular assays utilize immune cell lines or primary lymphocytes to assess immunomodulatory and antioxidant activities. Cells are cultured in appropriate medium with fetal bovine serum. Following treatment with Lobenzarit sodium (0.3-300 μM), endpoints include measurement of chemiluminescence from reactive oxygen species in activated phagocytes, cytokine production profiling, and assessment of T cell proliferation. These assays quantify the compound's ability to modulate immune responses and reduce oxidative stress.
|
| Animal Protocol |
Animal/Disease Models: SD (SD (Sprague-Dawley)) rat[2]
Doses: 10 and 50 mg/kg Route of Administration: IP; one time/day for 7 days Experimental Results: demonstrated anti-arthritic effects but not in T lymphocyte-depleted arthritis There was no therapeutic effect in rats. The primary in vivo model is adjuvant-induced arthritis in Sprague-Dawley rats. Arthritis is induced by appropriate immunization, followed by Lobenzarit sodium treatment via intraperitoneal injection at 10-50 mg/kg daily for 7 days. Efficacy is assessed through paw swelling measurements, joint inflammation scoring, and histopathological analysis. T lymphocyte depletion experiments are conducted to confirm the immunomodulatory mechanism. Additional models may include autoimmune disease models to evaluate prevention of autoimmune kidney disease. |
| ADME/Pharmacokinetics |
Lobenzarit sodium has a molecular weight of 335.65 g/mol and molecular formula C14H8ClNNa2O4. The compound is soluble in DMSO and has a melting point of 388°C (dec.). LogP is 0.883. The disodium salt form provides improved aqueous solubility compared to the free acid. Storage conditions: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Toxicological data are limited to preclinical observations. Lobenzarit sodium is supplied as a high-purity research reagent (≥98%) for laboratory use only, not for human consumption. In animal studies, the compound is generally well-tolerated at therapeutic doses. Standard toxicity assessments would include evaluation of hematological, hepatic, and renal parameters. No specific LD50 values are reported in the available literature.
|
| References | |
| Additional Infomation |
Lobenzarit sodium is an aminobenzoic acid.
Lobenzarit sodium is also known as Lobenzarit disodium and CCA. Related CAS numbers: 63329-53-3 (free acid) and 64808-48-6 (sodium salt). The compound is an aminobenzoic acid derivative and is used primarily as an antirheumatic agent in research. It is available as a white to off-white solid powder and is shipped at room temperature. |
| Molecular Formula |
C14H8CLNNA2O4
|
|---|---|
| Molecular Weight |
335.6502
|
| Exact Mass |
334.993
|
| CAS # |
64808-48-6
|
| Related CAS # |
63329-53-3 (free);64808-48-6 (sodium);
|
| PubChem CID |
47462
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
481ºC at 760 mmHg
|
| Melting Point |
388 °C(dec.)
|
| Flash Point |
244.7ºC
|
| LogP |
0.883
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
365
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QPJBONAWFAURGB-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C14H10ClNO4.2Na/c15-8-5-6-10(14(19)20)12(7-8)16-11-4-2-1-3-9(11)13(17)18;;/h1-7,16H,(H,17,18)(H,19,20);;/q;2*+1/p-2
|
| Chemical Name |
disodium;2-(2-carboxylatoanilino)-4-chlorobenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9793 mL | 14.8965 mL | 29.7929 mL | |
| 5 mM | 0.5959 mL | 2.9793 mL | 5.9586 mL | |
| 10 mM | 0.2979 mL | 1.4896 mL | 2.9793 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
